A double-blind, placebo-controlled trial of modafinil (200 mg/day) for methamphetamine dependence. - Wikidata - awgldk - TriplyDB

A double-blind, placebo-controlled trial of modafinil (200 mg/day) for methamphetamine dependence.

A double-blind, placebo-controlled trial of modafinil (200 mg/day) for methamphetamine dependence.

http://www.wikidata.org/entity/Q43517293

about

Modafinil as a catecholaminergic agent: empirical evidence and unanswered questions Future pharmacological treatments for substance use disorders Efficacy of psychostimulant drugs for amphetamine abuse or dependence Mirtazapine to reduce methamphetamine use: a randomized controlled trial Effect of modafinil on learning and task-related brain activity in methamphetamine-dependent and healthy individuals R-modafinil (armodafinil): a unique dopamine uptake inhibitor and potential medication for psychostimulant abuse Pharmacotherapy for stimulant-related disorders Pharmacotherapy of amphetamine-type stimulant dependence: an update Agonist replacement for stimulant dependence: a review of clinical research The neurocircuitry of illicit psychostimulant addiction: acute and chronic effects in humans High resolution mapping of modafinil induced changes in glutamate level in rat brain Pharmacotherapeutic agents in the treatment of methamphetamine dependence.Topiramate for the treatment of methamphetamine addiction: a multi-center placebo-controlled trial.Cognitive enhancement as a pharmacotherapy target for stimulant addiction Evaluation of modafinil effects on cardiovascular, subjective, and reinforcing effects of methamphetamine in methamphetamine-dependent volunteers.Randomized, double-blind, placebo-controlled trial of modafinil for the treatment of methamphetamine dependence.Pharmacological approaches to methamphetamine dependence: a focused review.Cocaine Addiction Treatments to improve Control and reduce Harm (CATCH): new pharmacological treatment options for crack-cocaine dependence in the Netherlands A randomized, placebo-controlled trial of sustained-release dextroamphetamine for treatment of methamphetamine addiction.Structure-Activity Relationships at the Monoamine Transporters for a Novel Series of Modafinil (2-[(diphenylmethyl)sulfinyl]acetamide) Analogues.Methamphetamine: an update on epidemiology, pharmacology, clinical phenomenology, and treatment literature Cognitive enhancers in the treatment of substance use disorders: clinical evidence.Treatments for methamphetamine abuse: a literature review for the clinician.BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP.Cognitive enhancement as a treatment for drug addictions The neurobiology of modafinil as an enhancer of cognitive performance and a potential treatment for substance use disorders.Dopaminergic mediation of the discriminative stimulus functions of modafinil in rats.Treatment of rats with an anti-(+)-methamphetamine monoclonal antibody shortens the duration of action of repeated (+)-methamphetamine challenges over a one month period Modafinil effects on reinstatement of methamphetamine seeking in a rat model of relapse.Acute modafinil effects on attention and inhibitory control in methamphetamine-dependent humans.Pharmacotherapeutics for substance-use disorders: a focus on dopaminergic medications.Safety and efficacy of varenicline to reduce positive subjective effects produced by methamphetamine in methamphetamine-dependent volunteers Modafinil for the treatment of methamphetamine dependence Chronic modafinil effects on drug-seeking following methamphetamine self-administration in rats.Investigating Methamphetamine Craving Using the Extinction-Reinstatement Model in the Rat.The ethics of elective psychopharmacology Psychostimulant addiction treatment.Efficacy and safety of psychostimulants for amphetamine and methamphetamine use disorders: a systematic review and meta-analysis Open-label pilot study of modafinil for methamphetamine dependence.The safety of modafinil in combination with oral ∆9-tetrahydrocannabinol in humans

P2860

Q21129426-95249FC5-1B9D-4E05-BB0B-620817BD464B Q22242633-C27B2533-0032-4A68-9C65-08DF13566DDA Q24198261-22B634C8-AAFF-4A09-B68E-7F43A31E1946 Q24603456-384D9D19-B7EC-4B4A-81E7-D20870F7670D Q24615244-3B17FF46-2B16-4319-9AD8-9D6378098BC0 Q24621917-1CCF0B9C-4B51-485B-A382-38BA8BD2AB59 Q26829186-76987C07-51DB-4A2C-B70A-CE43CF69547F Q26991936-7B978D3B-0776-42E3-84D6-D147934A286C Q27014854-6DCF6E63-2FB2-474A-9958-844F50428DF9 Q28236333-072B3B9D-C797-4CDA-BD61-6B713F59FD9E Q28541271-4B5D8BB1-5965-45B5-A8E6-326AD2904744 Q30235058-8C855556-5619-41BF-954C-DFC049698438 Q30418399-D5216FD4-AC78-4022-811E-EABFFBFA4908 Q33599983-68A7D5AB-5BD2-458A-9DFE-D802271A7327 Q33625390-32259BF8-EC0A-43A3-A99F-F1A1739D2215 Q33873511-B202A4D2-C7BC-463A-BEBB-A73F5FF486BE Q33906303-8A52253A-5DA1-44B0-8CEA-C41537C340CE Q33997733-94D11312-245B-450D-ABF7-4138CF22DC75 Q34156209-249335CC-7CF5-48CF-867E-B1C9200D0964 Q34166309-DB864CDE-486D-46F0-9753-4C9616245036 Q34181746-D3D543E5-0ED3-4FA9-83FB-9D20CA4E55D7 Q34183988-4BA13D91-DB27-4275-A162-447B85483833 Q34233794-E98B6144-E833-4341-8096-7AA3C2586D60 Q34277168-D7BA1633-8F7F-426D-A9F1-B00E3098D0CC Q34284329-EF477877-9A90-47EB-B894-341B2CAE96FF Q34363257-9D1FBC29-AE77-4A4D-8AEA-C6A406ABC697 Q34494307-5DF6F4E0-3718-4D85-B119-EC729AF1C5DC Q34602548-3A60D6AE-7CE7-41BE-B692-4EE146A0D3E0 Q34795068-4915555F-78D1-4B64-9252-A0ABA45629C8 Q35538176-970E5641-D680-46F0-A26A-6620891ABF5E Q35576598-26A76C5F-1B48-4CA3-9AEC-2395BF81F31F Q35580343-3A2B7B80-CF8D-4D26-8803-21328213F80D Q35583271-A303ABCA-DA56-4C8A-ACF3-02FB9E73D91A Q35673212-62DD0C3E-42E4-4176-86D8-C0A7BFFF07E5 Q35833732-90786604-90EA-40B7-AA8B-76AE22BAEBAF Q35886546-3D720FB7-EA7E-47FF-BBFE-13C96440798D Q35915231-107D014F-8EC3-43F2-BB93-2881488EBF1C Q36192104-4455F6A1-C516-4621-8D14-1160C25E901A Q36722528-9370A60E-DB68-45F0-9D02-6984F44571BE Q36820937-65C321A8-750B-48D5-A142-D250D887775D

P2860

A double-blind, placebo-controlled trial of modafinil (200 mg/day) for methamphetamine dependence.

http://www.wikidata.org/entity/Q43517293

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh

2009年學術文章

@zh-hant

name

A double-blind, placebo-contro ...... or methamphetamine dependence.

@en

A double-blind, placebo-contro ...... or methamphetamine dependence.

@nl

type

label

A double-blind, placebo-contro ...... or methamphetamine dependence.

@en

A double-blind, placebo-contro ...... or methamphetamine dependence.

@nl

prefLabel

A double-blind, placebo-contro ...... or methamphetamine dependence.

@en

A double-blind, placebo-contro ...... or methamphetamine dependence.

@nl

P1433

Q43517293-F5A588D2-1111-45D0-B130-70B4E4D9852D

P1476

Q43517293-71C80F53-8329-43DD-A625-DDD51859E52E

P2093

Q43517293-066FDD19-63E6-4FB9-9A8D-3BB276E0F5E2

Q43517293-41828637-0AC6-46E2-863B-08950D15502D

Q43517293-5732440E-9461-4B4F-A4CF-08B7C1A1623D

Q43517293-6ED33F56-0117-4C29-8C9A-FF01C2F40B83

Q43517293-83101CF2-7F25-4C8D-AD19-FBAE4FACB73C

Q43517293-9905485D-B5C0-4314-9B94-439AC141DFC9

Q43517293-DD3E877A-174F-487F-A8CF-81D603089547

Q43517293-E02BCDBE-54F2-4475-B366-A78A7949A1BE

Q43517293-F5A652FD-6812-4C07-BABD-053115D4F110

P304

Q43517293-989C7609-A83B-4842-9256-EE5F10D433D4

P31

Q43517293-806FA4BE-B5EB-409B-9BEC-B79AA85BF322

P356

Q43517293-9FE2B239-EF39-4286-B652-AD074B9AD13A

P407

Q43517293-CDE21CB7-BCC2-4739-8D27-FB3840FE4DCC

P433

Q43517293-97303069-FCE6-4FC9-884D-DD6DA8CEF114

P478

Q43517293-DC4E970E-088C-41E8-ADC6-18556983929E

P50

Q43517293-67EE92B0-9AAD-40B6-9A78-3082F9B16038

Q43517293-94954C9B-48E4-4D62-9A7D-DB2DE23D82C5

Q43517293-E432C9D2-8EA5-4A33-991D-3860514F2A03

P577

Q43517293-56F858F3-6CD4-4234-B116-0968B55D598B

P698

Q43517293-16BAFB4C-765B-421A-B8D2-907D3B2D69F6

P921

Q43517293-11949BEF-3666-4EC8-94A1-D1DCB85FF656

Q43517293-66F1A005-C283-41E7-8C4F-6333455F2618

P356

J.1360-0443.2008.02437.X

P1433

P1476

A double-blind, placebo-contro ...... or methamphetamine dependence.

@en

P2093

Alex Wodak

http://www.w3.org/2001/XMLSchema#string

Craig Rodgers

http://www.w3.org/2001/XMLSchema#string

Donna Brady

http://www.w3.org/2001/XMLSchema#string

Ingrid van Beek

http://www.w3.org/2001/XMLSchema#string

James Shearer

http://www.w3.org/2001/XMLSchema#string

John Lewis

http://www.w3.org/2001/XMLSchema#string

Rebecca McKetin

http://www.w3.org/2001/XMLSchema#string

Richard P Mattick

http://www.w3.org/2001/XMLSchema#string

Tim Slade

http://www.w3.org/2001/XMLSchema#string

P304

224-233

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1360-0443.2008.02437.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

104

http://www.w3.org/2001/XMLSchema#string

P50

Ingrid van Beek

P577

2009-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19149817

http://www.w3.org/2001/XMLSchema#string

P921